| Execution period | 60 months |
|---|
BSE filing, BSE: 544445. Summary written from the filing by ALFA Finder's alert engine.
Asston Pharmaceuticals Ltd: key numbers
- Share price
- ₹148.00
- Market cap
- ₹126.0 Cr
- Revenue (annual)
- ₹25.47 Cr
- Net profit (annual)
- ₹3.87 Cr
- P/E (TTM)
- 32.6×Sector 46.5×
- Promoter holding
- 39.48%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Asston Pharmaceuticals Ltd
All →Asston Pharmaceuticals Other Announcement
Asston Pharmaceuticals Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. It also disclosed a recent preferential allotment of 24.10 lakh equity shares.
Asston Pharmaceuticals Other Announcement
Asston Pharmaceuticals Limited announced a change in the company's registered office address within the same city, effective from 15th October 2026.
Asston Pharmaceuticals Capital Structure Change
The company submitted a revised shareholding pattern following the allotment of 24,10,431 equity shares through a preferential allotment dated September 5, 2026.
Asston Pharmaceuticals Board Meeting Date
Asston Pharmaceuticals Limited has scheduled a board meeting on 13 October 2026 to consider other business matters. The company's trading window remains closed until 17 October 2026.
Asston Pharmaceuticals Annual General Meeting
Asston Pharmaceuticals Limited concluded its 7th Annual General Meeting on September 29, 2026. Shareholders considered resolutions including adoption of financial statements and director remuneration increases.
Asston Pharmaceuticals Other Announcement
Asston Pharmaceuticals Ltd submitted its quarterly shareholding pattern disclosure, detailing the shareholding status of promoters and public shareholders for the period ended March 2026.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.